Original-Research: VOQUZ Labs AG (von NuWays AG): BUY
Original-Research: VOQUZ Labs AG - von NuWays AG
Einstufung von NuWays AG zu VOQUZ Labs AG
Unternehmen: VOQUZ Labs AG
ISIN: DE000A3CSTW4
Anlass der Studie: Update
Empfehlung: BUY
seit: 21.11.2023
Kursziel: € 20,00
Kursziel auf Sicht von: 12 Monaten
Letzte Ratingänderung:
Analyst: Philipp Sennewald
Outlook gets cloudier amid macro-headwinds; chg.
After VOQUZ has shown stellar top-line growth in the past (2019-‘22 CAGR of 38%), the company reported a weak set of H1, clearly reflecting the deteriorating macro environment.
Despite a 14% yoy increase in order intake, H1 sales only grew by 3% yoy to € 1.9m (eNuW: € 2.5m) following prolonged sales cycles. Moreover, a higher share of consulting orders, which in general have a longer revenue recognition period, weighed on top-line development.
Following the uninspiring sales development, H1 EBITDA turned negative with € -0.5m (vs € 0.1m at H1’22). The main reason for this were rapidly increasing personnel expenses (+93% yoy to € 1.1m) which is due to the incorporation of a subsidiary in Romania as well as increased sales and marketing capacities. Following the intensified marketing efforts (e.g. conferences in US, Australia) other operating expenses also increased by 16% yoy to € 1.2m.
Although the seasonally strong H2 (especially Q4) is seen to show an improved operating performance with a sequential growth acceleration (eNuW: +7.5%) and a slightly positive EBITDA (eNuW: € 0.3m), VOQUZ looks set to report negative FY EBITDA of € 0.2m.
However, the company’s mid-term prospects remain intact, in our view. Especially with regards to the still lagging SAP S/4HANA migration (33% as of Q2’23). As adoption rates are seen to exponentially increase, VOQUZ looks set to be one of the main beneficiaries with its new software solution VisoryQ, which helps clients to set up an efficient ERP strategy. On top of this, promising cross- and up-selling potentials are in the books, which is becomes visibile in the high share of existing customers in order intake. Against this backdrop, we expect dynamic top-line development combined with steadily expanding margins going forward on the back of economies of scale.
In light of the recent weakness as well as the strong underlying mid-term trends combined with the scalability of the capital-light business model, the stock looks undervalued trading at only 1.3x EV/Sales ‘23e.
Reiterate BUY with a reduced PT of € 20.00 (old: € 32.00) based on DCF.
Die vollständige Analyse können Sie hier downloaden:
http://www.more-ir.de/d/28349.pdf
Die Analyse oder weiterführende Informationen zu dieser können Sie hier downloaden
www.nuways-ag.com/research.
Kontakt für Rückfragen
NuWays AG - Equity Research
Web: www.nuways-ag.com
Email: research@nuways-ag.com
LinkedIn: https://www.linkedin.com/company/nuwaysag
Adresse: Mittelweg 16-17, 20148 Hamburg, Germany
++++++++++
Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim oben analysierten Unternehmen befinden sich in der vollständigen Analyse.
++++++++++
-------------------übermittelt durch die EQS Group AG.-------------------
Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | ||
| Sales1 | 1,56 | 2,01 | 2,96 | 3,89 | 4,72 | 5,26 | 6,05 | |
| EBITDA1,2 | 0,13 | 0,09 | 0,66 | 0,96 | 0,62 | 0,49 | 1,10 | |
| EBITDA-Margin3 | 8,33 | 4,48 | 22,30 | 24,68 | 13,14 | 9,32 | 18,18 | |
| EBIT1,4 | 0,03 | 0,24 | 0,45 | 0,62 | 0,26 | 0,04 | 0,00 | |
| EBIT-Margin5 | 1,92 | 11,94 | 15,20 | 15,94 | 5,51 | 0,76 | 0,00 | |
| Net Profit (Loss)1 | -0,02 | 0,29 | 0,44 | 0,48 | 0,06 | -0,08 | 0,00 | |
| Net-Margin6 | -1,28 | 14,43 | 14,87 | 12,34 | 1,27 | -1,52 | 0,00 | |
| Cashflow1,7 | -0,07 | 0,35 | 0,40 | 0,58 | 0,08 | -0,04 | 0,00 | |
| Earnings per share8 | 0,00 | 0,28 | 0,42 | 0,46 | 0,06 | -0,07 | 0,30 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Menold Bezler
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| VOQUZ Labs | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A3CSTW | DE000A3CSTW4 | AG | 7,77 Mio € | 28.07.2021 | 9F4MG83M+WF | |
| PE 2025e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 15,74 | 18,86 | 0,64 | 30,58 | 4,03 | -194,25 | 1,48 |
|
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 02.07.2024 | 27.09.2024 | 23.05.2024 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -3,92% | -19,15% | +48,00% | +48,00% | -81,50% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
